KRAS and colorectal carcinoma: Therefore, in the ATOM study, we planned a randomized phase II clinical study to conduct an exploratory comparison of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab in KRAS wild‐type, difficult‐to‐resect, liver‐only metastases from CRC.